In brief
- Otsuka has finalized its acquisition of Transcend Therapeutics, the biotech firm developing TSND-201, a methylone derivative with MDMA-like effects for post-traumatic stress disorder (PTSD).
- A Phase 2 trial, published in JAMA Psychiatry, demonstrated a significant reduction in symptoms after only four weekly doses, without the need for the lengthy assisted psychotherapy sessions required by the MDMA protocol.
- The molecule has already received FDA Breakthrough Therapy designation and a priority review voucher; a Phase 3 trial is underway, with results expected by late 2027.
On June 15, the Japanese pharmaceutical company Otsuka completed its acquisition of Transcend Therapeutics for up to $1.225 billion. The New York-based company is developing TSND-201, a formulation of methylone—a compound chemically related to MDMA—which achieved rapid and sustained improvements in people with severe PTSD during its Phase 2 trial.
An MDMA relative without the “trip”
Methylone acts on the same dopamine, serotonin, and norepinephrine transporters as MDMA, which may explain its ability to promote neuronal plasticity and facilitate the extinction of trauma-associated fear. The key difference is that TSND-201 barely activates the 5-HT2A receptor, which mediates many of the intense subjective effects of classic psychedelics and MDMA itself. In practice, this allowed the drug to be administered in the trial with “non-directive” clinical support, avoiding the multi-hour structured psychotherapy sessions required by the MDMA protocol. This also indirectly addresses a problem that hindered the MDMA therapy approval application in 2024: the difficulty of maintaining a double-blind study when participants can tell they have received the active substance. Those interested in how that protocol works can consult our Psychedelics Guide on MDMA.
Phase 2 trial data
The study, known as IMPACT-1, included 65 people with PTSD across 16 centers in the United States, the United Kingdom, and Ireland, and its results were published on February 18 in JAMA Psychiatry. Those who received TSND-201 achieved a mean reduction of 23.3 points on the CAPS-5 scale by day 64, compared to 13.6 points in the placebo group (a difference of 9.64 points; 90% confidence interval, -16.48 to -2.80; p=0.01). Improvement was noticeable by the tenth day. 57.1% of those who took the drug responded to treatment compared to 19.2% in the placebo group, and 60.7% no longer met the diagnostic criteria for PTSD compared to 30.8% in the control group. Adverse effects—headache, loss of appetite, nausea, dizziness—were mild, transient, and limited to the day of dosing; no one dropped out of the study for this reason. With this data, the FDA granted TSND-201 Breakthrough Therapy designation in July 2025 and, in April 2026, one of its first national priority review vouchers, intended to shorten regulatory review to one or two months once the application is submitted. The Phase 3 trial, called EMPOWER-1, is currently recruiting 300 participants and is expected to conclude by late 2027.
What this implies
PTSD affects more than 13 million people per year in the United States alone and has not seen a new approved drug in nearly 25 years, so any alternative that passes Phase 3 would be significant in terms of treatment access. It is advisable to maintain the usual caution: this is still a Phase 2 trial with a modest sample size, without Phase 3 results or regulatory approval, and a corporate acquisition is not equivalent to definitive clinical validation. Furthermore, there is currently no evidence that methylone offers the same safety profile outside of a controlled trial with standardized pharmaceutical doses—something to keep in mind from a harm reduction perspective when compared to the unsupervised use of substances in the same chemical family. You can read more about these principles of informed use and risk minimization in our section on harm reduction and responsible use.
Source
- Jones A, Kelmendi B, et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry, February 18, 2026.
- Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Completes Acquisition of Transcend Therapeutics. Otsuka Pharmaceutical, June 15, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
